Research Paper Volume 13, Issue 3 pp 4522—4551

Hsa_circ_0000199 facilitates chemo-tolerance of triple-negative breast cancer by interfering with miR-206/613-led PI3K/Akt/mTOR signaling

Clinical value of circRNA AKT3 in triple-negative breast cancer (TNBC). (A) Fold change of AKT3-derived circRNAs were determined in BC tissues of other subtypes (i.e. non-TNBC) as relative to normal tissues, and also in TNBC tissues as relative to BC tissues of other subtypes. (B) Hsa

Figure 1. Clinical value of circRNA AKT3 in triple-negative breast cancer (TNBC). (A) Fold change of AKT3-derived circRNAs were determined in BC tissues of other subtypes (i.e. non-TNBC) as relative to normal tissues, and also in TNBC tissues as relative to BC tissues of other subtypes. (B) Hsa_circ_0000199 expression was compared among normal tissues, TNBC tissues and BC tissues of other subtypes. ***: P<0.001. (C) Hsa_circ_0000199 expression was measured among MCF-10A, MDA-MB-231, MDA-MB-468, SK-BR-3 and MCF-7 cell lines. **: P<0.01; ***: P<0.001. (D) Hsa_circ_0000199 expression was associated with 3-year survival of TNBC patients.